Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648349 | Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg | PHASE1 | COMPLETED | 72 | — | — | May 1, 2003 | Jun 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rabeprazole Sodium Delayed-Release Tablets 20 mg |
| 2 | ACTIVE_COMPARATOR | Aciphex® Delayed-Release Tablets 20 mg |
| Name | Type | Description |
|---|---|---|
| Rabeprazole Sodium Delayed-Release Tablets 20 mg | DRUG | 20mg, single dose fasting |
| Aciphex® Delayed-Release Tablets 20 mg | DRUG | 20mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administratio...